01583nam a2200229   4500001000800000005001700008007000300025008004100028040000800069041000800077100003100085245007800116300002500194520087000219650002801089650004001117650002901157650001201186650002401198650002801222773010301250ESSALUD20260902130441.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aTobias, Deirdre K. eAutor  aGetting Serious about Tickborne Diseases — Shifting Research Priorities  apáginas: 1971-1973  aThe incidence of Lyme disease has steadily increased since the discovery of the causative agent, Borrelia burgdorferi, in 1982. In recent years, an estimated 500,000 cases have been diagnosed each year in the United States, resulting in nearly $1 billion in annual health care costs. Cases of other tickborne diseases, including anaplasmosis, babesiosis, and Powassan virus infection, have also increased (see graphs). Despite 40 years of research aimed at controlling Lyme disease, there are currently no available prevention methods that significantly reduce disease incidence in humans. Failure to address this epidemic is in part a result of the misdirection of research efforts, which have emphasized clinical disease and pathogen microbiology rather than the root cause of Lyme disease: the infected tick vectors in the environment, which remain uncontrolled.  aINFECCIONES BACTERIANAS  aMEDICAMENTOS, DISPOSITIVOS Y LA FDA  aINFECCIONES PARASITARIAS  aVACUNAS  aINFECCIONES VIRALES  aSALUD PÚBLICA GENERAL0 022717dMassachusetts NEJM GroupoNEJM013tThe New England Journal of Medicine wESSALUDx0028-4793